PDCD1 and neoplasm: Hence, the diverse repertoire of immunosuppressive and tumor-promoting Gal-9-binding receptors highlights its potential as a cancer immunotherapeutic target, either alone or in combination with approved or preclinical inhibitors of immune checkpoint receptors, such as PD-1, or other molecules.